Please ensure Javascript is enabled for purposes of website accessibility
Patrick Bafuma

Patrick Bafuma

TMFfuma102

Recent articles

GettyImages-875110736

3 Last-Minute Healthcare Stocking Stuffers

Here are three stocks sure to pique the interest of that special someone.


GettyImages-826300274

10x Genomics Stock: Bull vs. Bear

After a hot start, the stock has recently lagged the market. Is now a good time to buy?


GettyImages-1322901776

Better Buy: Ocugen or Novavax?

Will either of these hopeful vaccine makers continue to thrash the market?


GettyImages-1036131880

Better Buy: Bristol Myers Squibb vs. Merck

Which pharma giant is right for you?


GettyImages-1322901776

Pfizer: Bull vs. Bear

The pharmaceutical giant has lagged the market over the past decade, but will the fight against COVID-19 change that?

GettyImages-981733948

Big Pharma Is Going Holiday Shopping. Who's Next?

After an infusion of cash from COVID-19 treatments, many companies are on the lookout for acquisitions.


GettyImages-1288161696

Binge Watching Dopesick? Here Are 3 Stocks That Involve an Opioid-Free Recovery

Check out these companies utilizing non-pharmaceutical means to optimize America's health.


GettyImages-1266494470

Should Biogen Investors Be Preparing for the Worst?

With sagging sales and lackluster data in a recent trial, what does the future hold for shareholders?


GettyImages-1224413537

Was Atea Pharmaceutical's Flop Predictable?

Were warning signs there for investors all along?


GettyImages-526637899

Up Over 500% in the Last 5 Years, Can This Biotech Continue Its Hot Streak?

Codexis is leveraging its core technology to create more effective life science tools.

GettyImages-146263975

Is This Beaten Down Biotech a Bad News Buy?

It has lagged the market over the last five years but with a promising gene therapy, is Sarepta worth another look?


GettyImages-1224413537

2 Tricks and a Treat for Gene Therapy Investors

It looks like the gene therapy market is a haunted house, but growing biotech Repligen might be the treat investors need this Halloween.


GettyImages-1251894563

Can This Duo Outperform Merck and Ridgeback Biotherapeutics' COVID Treatment?

This partnership is showing early efficacy in the race for an oral COVID-19 treatment, but Atea and Roche are on their haunches.


GettyImages-904794342

This Promising Healthcare Stock Is Down 50% From Its Highs; Should You Buy the Dip?

Novocure has been fantastic for investors, up over 1,600% in the past five years. But in the past six months, shareholders have been on a roller coaster.


GettyImages-981733948

Pfizer's CEO Wants to Go Shopping: 3 Potential Companies on His Radar

Projecting over $33 billion in COVID-19 vaccine revenue alone in 2021, CEO Albert Bourla wants to beef up Pfizer's pipeline.

GettyImages-1251894563

This High-Risk, High-Reward Biotech Could Make COVID Less Deadly -- and Make Investors Money

An effective oral antiviral therapy for the coronavirus may be around the corner.


GettyImages-1251894563

Is This Small-Cap Biotech a Buy After Its Second Approved Gene Therapy?

After receiving yet another treatment approval from regulators, Bluebird Bio looks like a bargain.


GettyImages-904794342

This Under-the-Radar Dementia Treatment Could Reward Investors

Want to dabble in the market for Alzheimer's therapies but avoid Biogen? Look no further.


GettyImages-1306664812

2 Reasons to Buy Intellia -- and 1 Big Reason Why I Won't

After the clinical-stage biotech publicized promising data for its gene-editing treatment of a rare and fatal disease, its stock skyrocketed.


GettyImages-200490727-002

Could This Recently IPOed Medical Device Maker Make You Rich?

Small-cap epilepsy treatment specialist NeuroPace looks a lot like Abiomed did in its early days.